Cost- Effectiveness of Avatrombopag for the Treatment of Thrombocytopenia in Patients with Chronic Liver Disease

References

• Giannini EG. Review article: thrombocytopenia in chronic liver disease and pharmacologic treatment options. Aliment Pharmacol Ther. 2006;23:1055–1065. doi:10.1111/j.1365-2036.2006.02889.x
   PubMed Web of Science ®Google Scholar
• Smock KJ, Perkins SL. Thrombocytopenia: an update. Int J Lab Hematol. 2014;36:269–278. doi:10.1111/ijlh.12214
   PubMed Web of Science ®Google Scholar
• Kurokawa T, Ohkohchi N. Platelets in liver disease, cancer and regeneration. World J Gastroenterol. 2017;23:3228–3239. doi:10.3748/wjg.v23.i18.3228
   PubMed Web of Science ®Google Scholar
• Cocero N, Bezzi M, Martini S, et al. Oral surgical treatment of patients with chronic liver disease: assessments of bleeding and its relationship with thrombocytopenia and blood coagulation parameters. J Oral Maxillofac Surg. 2017;75:28–34. doi:10.1016/j.joms.2016.08.033
   Web of Science ®Google Scholar
• Patel IJ, Rahim S, Davidson JC, et al. Society of Interventional Radiology consensus guidelines for the periprocedural management of thrombotic and bleeding risk in patients undergoing percutaneous image-guided interventions-Part II: recommendations: endorsed by the Canadian Association for Interventional Radiology and the Cardiovascular and Interventional Radiological Society of Europe. J Vasc Interv Radiol. 2019;30:1168–1184 e1161. doi:10.1016/j.jvir.2019.04.017
   PubMed Web of Science ®Google Scholar
• Poordad F. Review article: thrombocytopenia in chronic liver disease. Aliment Pharmacol Ther. 2007;26:5–11. doi:10.1111/j.1365-2036.2007.03510.x
   PubMed Web of Science ®Google Scholar
• Barnett CL, Mladsi D, Vredenburg M, et al. Cost estimate of platelet transfusion in the United States for patients with chronic liver disease and associated thrombocytopenia undergoing elective procedures. J Med Econ. 2018;21(8):827–834. doi:10.1080/13696998.2018.1490301
   PubMed Web of Science ®Google Scholar
• Terrault N, Chen YC, Izumi N, et al. Avatrombopag before procedures reduces need for platelet transfusion in patients with chronic liver disease and thrombocytopenia. Gastroenterology. 2018;155:705–718. doi:10.1053/j.gastro.2018.05.025
   PubMed Web of Science ®Google Scholar
• Terrault NA, Hassanein T, Howell CD, et al. Phase II study of avatrombopag in thrombocytopenic patients with cirrhosis undergoing an elective procedure. J Hepatol. 2014;61:1253–1259. doi:10.1016/j.jhep.2014.07.007
   PubMed Web of Science ®Google Scholar
• Peck-Radosavljevic M, Simon K, Iacobellis A, et al. Lusutrombopag for the treatment of thrombocytopenia in patients with chronic Liver Disease Undergoing Invasive Procedures (L-PLUS 2). Hepatology. 2019;70:1336–1348. doi:10.1002/hep.30561
   PubMed Web of Science ®Google Scholar
• BLS [Bureau of Labor Statistics]. Inflation & prices: medical care services in U.S. city average, all urban consumers, not seasonally adjusted. 2018. Available from: https://www.bls.gov/data/. Accessed May 2, 2018.
   Google Scholar
• Mulpleta prescribing information. Mulpleta (Lusutrombopag). Florham Park, NJ: Shionogi Inc; 2018. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210923s000lbl.pdf. Accessed September 7, 2018.
   Google Scholar
• Afdhal NH Lusutrombopag for Treatment of Thrombocytopenia in Patients Undergoing Non-Emergency Invasive Procedures: Results from An International Phase 3, Randomized, Double-Blind, Placebo-Controlled Study (L-PLUS 2). Presented at the American Association of the Study of Liver Diseases Annual Meeting; 2017. Washington, DC.
   Google Scholar
• Red Book Online. Ann Arbor, MI. Truven Health Analytics; 2019. Available from: http://www.micromedexsolutions.com. Accessed June 20, 2019.
   Google Scholar
• Walsh KA, Lewis DA, Clifford TM, et al. Risk factors for venous thromboembolism in patients with chronic liver disease. Ann Pharmacother. 2013;47:333–339. doi:10.1345/aph.1R496
   Web of Science ®Google Scholar
• Sanders GD, Neumann PJ, Basu A, et al. Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses: second panel on cost-effectiveness in health and medicine. JAMA. 2016;316:1093–1103. doi:10.1001/jama.2016.12195
   PubMed Web of Science ®Google Scholar
• HCUP NIS Database Documentation. Healthcare Cost and Utilization Project (HCUP). 2019. Available from: https://www.hcup-us.ahrq.gov/db/nation/nis/nisdbdocumentation.jsp. Accessed July 21, 2020.
   Google Scholar
• Mladsi DM, Barnett CL, Kaye JA. Psy2 – identification of potential bias from data sources and study designs used to estimate platelet transfusion adverse event rates. Value in Health. 2018;21:S436. doi:10.1016/j.jval.2018.09.2579
   Web of Science ®Google Scholar
• Helenius-Hietala J, Åberg F, Meurman JH, et al. Oral surgery in liver transplant candidates: a retrospective study on delayed bleeding and other complications. Oral Surg Oral Med Oral Pathol Oral Radiol. 2016;121:490–495. doi:10.1016/j.oooo.2016.01.025
   Web of Science ®Google Scholar
• Rockey DC, Caldwell SH, Goodman ZD, et al. Liver biopsy. Hepatology. 2009;49:1017–1044. doi:10.1002/hep.22742
   PubMed Web of Science ®Google Scholar
• Fontaine MJ, Chung YT, Rogers WM, et al. Improving platelet supply chains through collaborations between blood centers and transfusion services. Transfusion. 2009;49:2040–2047. doi:10.1111/j.1537-2995.2009.02236.x
   PubMed Web of Science ®Google Scholar
• Toner RW, Pizzi L, Leas B, et al. Costs to hospitals of acquiring and processing blood in the US: a survey of hospital-based blood banks and transfusion services. Appl Health Econ Health Policy. 2011;9:29–37. doi:10.2165/11530740-000000000-00000
   PubMedGoogle Scholar
• Brown RS, Bentley R, Cai B, et al. The clinical and economic burden of patients with chronic liver disease and thrombocytopaenia receiving platelet transfusions during planned invasive procedures. GastroHep. 2019;1:236–248. doi:10.1002/ygh2.357
   Google Scholar
• Whitaker B, Rajbhandary S, Kleinman S, et al. Trends in United States blood collection and transfusion: results from the 2013 AABB blood collection, utilization, and patient blood management survey. Transfusion. 2016;56:2173–2183. doi:10.1111/trf.13676
   PubMed Web of Science ®Google Scholar
• Brown RS Jr. Review article: a pharmacoeconomic analysis of thrombocytopenia in chronic liver disease. Aliment Pharmacol Ther. 2007;26:41–48. doi:10.1111/j.1365-2036.2007.03505.x
   PubMed Web of Science ®Google Scholar
• Mohd Hanafiah K, Groeger J, Flaxman AD, et al. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology. 2013;57:1333–1342. doi:10.1002/hep.26141
   PubMed Web of Science ®Google Scholar
• Jakovljevic M, Jakab M, Gerdtham U, et al. Comparative financing analysis and political economy of noncommunicable diseases. J Med Econ. 2019;22:722–727. doi:10.1080/13696998.2019.1600523
   PubMed Web of Science ®Google Scholar
• Jakovljevic M, Matter-Walstra K, Sugahara T, et al. Cost-effectiveness and resource allocation (CERA) 18 years of evolution: maturity of adulthood and promise beyond tomorrow. Cost Eff Resour Alloc. 2020;18:15. doi:10.1186/s12962-020-00210-2
   PubMed Web of Science ®Google Scholar
• Doptelet prescribing information. DOPTELET (Avatrombopag). Durham, NC: Dova Pharmaceuticals, Inc.; 2018.
   Google Scholar
• Straube S, Tramer MR, Moore RA, et al. Mortality with upper gastrointestinal bleeding and perforation: effects of time and NSAID use. BMC Gastroenterol. 2009;9:41. doi:10.1186/1471-230X-9-41
   PubMed Web of Science ®Google Scholar
• Stepanova M, Clement S, Wong R, et al. Patients with diabetes and chronic liver disease are at increased risk for overall mortality: a population study from the United States. Clin Diabetes. 2017;35:79–83. doi:10.2337/cd16-0018
   PubMedGoogle Scholar
• Fineberg SJ, Oglesby M, Patel AA, et al. The incidence and mortality of thromboembolic events in lumbar spine surgery. Spine (Phila Pa). 1976;2013(38):1154–1159.
   Google Scholar